welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Prognostic Factors Affecting Duchenne Muscular Dystrophy
study id #: NCT03372655
condition: Duchenne Muscular Dystrophy
status: not yet recruitingpurpose:
Determination of prognostic factors affecting ambulation of duchenne muscular dystrophy
mechanism of action: No pharmaceutical intervention
last updated: November 18, 2019
start date: January 1, 2018
estimated completion: January 1, 2019
size / enrollment: 82
Duchenne muscular dystrophy is the most common herditary muscular disease , it lead to loss of ambulation in early teenageers . It lead to early death at the mean age of 19 years
- Ten meter walking test [Time Frame: 2018 - 2019]
- Muscle strength [Time Frame: 2018- 2019]
• Eligible Sexes: male
Any male pt diagnosed as Duchenne muscular dystrophy by typical clinical picture & shooting serum CPK level & EMG study or biopsy & age 10 to 18yrs old
Female patient' age below 10 yrs old or above 18 yrs old. Patient with autoimmune disease or malignancy.
The Role of Family Functioning in Promoting Adaptation in Siblings of Individuals With Duchenne Muscular Dystrophy (...Background: We want to learn more about ...
Duchenne Muscular Dystrophy < 18y in Norway: Genotype/Phenotype, Growth, Puberty, Bone Health and Quality of LifeThe study will give a consent based epid...
Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular DystrophiesThe study will include 120 participants ...
Patient education: Overview of muscular dystrophies (Beyond the Basics)Muscular dystrophy is an inherited disor...
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
Pediatric Radio Frequency Coils GenericThe purpose of this study is to evaluate...
Open Label Study of GSK2402968 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to explore ...
Stomatognathic function in Duchenne muscular dystrophy: a case-control studyAim: This study aimed to analyse electr...
Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Musc...Catabasis Pharmaceuticals, Inc. (NASDAQ:...
Duchenne Muscular Dystrophy and its Treatment Optionshttps://www.youtube.com/watch?v=Q0ejNx2k...